NCT07790237 evaluates Dermial® at 60 mg/day against placebo in 146 healthy women aged 35–65 with physiological signs of skin ageing. The design is randomised, parallel and masked for participants, care providers, investigators and outcome assessors.

The planned duration is twelve weeks. The protocol measures periocular glow using a Skin-Glossymeter, with interim measurements at weeks three and six, alongside hydration, radiance and other skin-quality outcomes.

The study architecture informs R&D and scientific marketing, but does not yet support efficacy language. Effect size, clinical relevance and consistency across endpoints can only be judged after publication.

Why it matters

Low dose, a relatively large sample and instrumental measurements provide a useful benchmark for beauty-from-within development.

Evidence limit

The active study is no longer recruiting and has no published results. Registration does not demonstrate efficacy, comparative safety or a perceptible benefit.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · ClinicalTrials.gov ↗